HTI immunogen (Aelix Therapeutics)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHTI immunogen (Aelix Therapeutics)
Drug Alias NameMVA.HTIDNA.HTI
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAelix Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncUniversity Of OxfordIrsicaixa +[4] 
Inactive CompaniesN/A
Active IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A